UNSPSC 51282533: Cefmepidium chloride

This classification denotes a cephalosporin antibiotic with the molecular formula C23H25N6O8S3.Cl, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 726233N8L3, chemically known as 4-((((6r,7r)-7-(2-(2-amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)thio)-1-methylpyridinium chloride 7,2-(z)-(o-(1-carboxy-1-methylethyl)oxime) s-oxide. but more generally known as cefmepidium chloride, which bears US NIH Compound Identifier 9589472.

UNSPSC 51282533 Cefmepidium chloride is a Commodity code with minimal recent activity directly aligned to its nominal scope. State and local procurement records show no solicitations for cefmepidium chloride specifically; the code appears underutilized or misapplied in recent state and local contracting activity. When the code does surface in procurement records, it is tagged to opportunities focused on pharmaceutical procurement more broadly—including naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing arrangements, and direct-to-manufacturer prescription programs—rather than to this specific active pharmaceutical ingredient. The issuing bodies pursuing pharmaceutical-related contracts span state health and human services agencies (Texas HHS Commission), county public health departments (Seminole County, Florida), municipal fire and rescue services (City of Tampa), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving participating state and local facilities across multiple states including Oregon).

Activity under pharmaceutical codes in this family is concentrated in Florida, Texas, and Minnesota-based jurisdictions, with cooperative purchasing vehicles extending reach across multiple state and local entities. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023, 1,900 units of naloxone and 800 deactivation systems annually); the City of Tampa's IFB for medical and first aid supplies to the Fire Department Rescue Division (due March 13, 2026, 169 line items, estimated contract value $700,000, sheltered for Small Local Business Enterprises with a 5% bid discount); the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026, distributed through authorized wholesalers effective July 1, 2026); and the Texas HHS Commission's RFI on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (response due April 3, 2026, exploratory phase prior to formal RFP). Firms pursuing this code should verify that pharmaceutical opportunities are tagged correctly and evaluate whether their product offerings align to actual state and local purchasing needs, as the code's technical scope does not match current solicitation patterns.